The purpose of this study is to investigate the effect of empagliflozin on oxidative stress
in patients with type 2 diabetes. The association is examined by comparing the difference in
oxidative modifications before and after 14 days treatment with 25 mg empagliflozin compared
to placebo treatment. The study is randomised, double-blinded, and placebo controlled. Each
treatment group consists of 17 males with type 2 diabetes. Oxidative modifications are
measured by urinary excretion of 8-oxo-7,8-dihydro-2'-deoxyguanosine and
8-oxo-7,8-dihydroguanosine. A student t-test will be performed to compare the drug treatment
with placebo. The results will be published in a peer-review journal.